Salvador-Martin, SaraKaczmarczyk, BartoszAlvarez, RebecaNavas-Lopez, Victor ManuelGallego-Fernandez, CarmenMoreno-Alvarez, AnaSolar-Boga, AlfonsoSanchez, CesarTolin, MarVelasco, MartaMuñoz-Codoceo, RosanaRodriguez-Martinez, AlejandroVayo, Concepcion ABossacoma, FerranPujol-Muncunill, GemmaFobelo, Maria JMillan-Jimenez, AntonioMagallares, LorenaMartinez-Ojinaga, EvaLoverdos, InesEizaguirre, Francisco JBlanca-Garcia, Jose AClemente, SusanaGarcia-Romero, RuthMerino-Bohorquez, VicenteGonzalez-de-Caldas, RafaelVazquez, EnriqueDopazo, AnaSanjurjo-Saez, MariaLopez-Fernandez, Luis A2023-02-092023-02-092021-01-08Salvador-Martín S, Kaczmarczyk B, Álvarez R, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, et al. Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Pharmaceutics. 2021 Jan 8;13(1):771999-4923http://hdl.handle.net/10668/16953Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or 0.6 or Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Crohn diseaseAdalimumabBiomarkerGene expressionInflammatory bowel diseaseInfliximabUlcerative colitisÁrea de Gestión Sanitaria Sur de SevillaGenesTumor Necrosis Factor-alphaCohort StudiesPharmaceutical PreparationsBiomarkersInflammatory Bowel Diseasesresearch article33429950open accessGenesFactor de necrosis tumoral alfaAncianoBiomarcadoresEstudios de cohortesEnfermedades inflamatorias del intestino10.3390/pharmaceutics13010077PMC7830359https://www.mdpi.com/1999-4923/13/1/77/pdf?version=1610447336https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830359/pdf